|
|
|
|
|
|
|
Positive
|
Late |
Frontera et al., Research Square, doi:10.21203/rs.3.rs-94509/v1 (Preprint) |
death, ↓37.0%, p=0.01 |
Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study |
| Retrospective 3,473 hospitalized patients showing 37% lower mortality with HC Q+zinc.
PSM aHR 0.63, p=0.015
regression aHR 0.76, p = 0.023 |
|
Positive
|
Late treatment study
|
| Frontera et al., Research Square, doi:10.21203/rs.3.rs-94509/v1 (Preprint) |
| Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study |
Retrospective 3,473 hospitalized patients showing 37% lower mortality with HC Q+zinc.PSM aHR 0.63, p=0.015
regression aHR 0.76, p = 0.023
death, ↓37.0%, p=0.01, PSM
death, ↓24.0%, p=0.02, regression
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
PrEP |
Berrocal et al., Research Square, doi:10.21203/rs.3.rs-95524/v1 (Preprint) |
death, ↓44.8%, p=0.23 |
Zinc and Vitamin a Deficiency Predisposes to the Need for Intubation and Icu Admission in Patients With COVID-19. An Observational Study |
| Retrospective 120 hospitalized patients showing zinc deficiency associated with a higher ICU admission rate (61.8% vs.29%; p = 0.002) and a higher rate of intubation (87.5% vs. 12.5%; p = 0.002). |
|
Positive
|
Pre-Exposure Prophylaxis study
Pre-Exposure Prophylaxis study
|
| Berrocal et al., Research Square, doi:10.21203/rs.3.rs-95524/v1 (Preprint) |
| Zinc and Vitamin a Deficiency Predisposes to the Need for Intubation and Icu Admission in Patients With COVID-19. An Observational Study |
| Retrospective 120 hospitalized patients showing zinc deficiency associated with a higher ICU admission rate (61.8% vs.29%; p = 0.002) and a higher rate of intubation (87.5% vs. 12.5%; p = 0.002).
death, ↓44.8%, p=0.23
ICU admission, ↓53.0%, p=0.003
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
Early |
Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3) (Peer Reviewed) |
death, ↓79.4%, p=0.12 |
COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxych loroquine and Azithromycin: A Retrospective Case Series Study |
| 79% lower mortality and 82% lower hospitalization with early HC Q+AZ+Z. Retrospective 518 patients (141 treated, 377 control). |
|
Positive
|
Early treatment study
|
| Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3) (Peer Reviewed) |
| COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxych loroquine and Azithromycin: A Retrospective Case Series Study |
| 79% lower mortality and 82% lower hospitalization with early HC Q+AZ+Z. Retrospective 518 patients (141 treated, 377 control).
death, ↓79.4%, p=0.12
hospitalization, ↓81.6%, p<0.001
(odds ratio converted to relative risk)
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
PrEP |
Heller et al., Redox Biology, doi:10.1016/j.redox.2020.101764 (Peer Reviewed) |
Prediction of Survival Odds in COVID-19 by Zinc, Age and Selenoprotein P as Composite Biomarker |
| Analysis of 35 COVID-19 patients showing a significant correlation for serum zinc levels between COVID-19 patients and controls, and between COVID-19 survivors and non-survivors. |
|
Positive
|
Pre-Exposure Prophylaxis study
Pre-Exposure Prophylaxis study
|
| Heller et al., Redox Biology, doi:10.1016/j.redox.2020.101764 (Peer Reviewed) |
| Prediction of Survival Odds in COVID-19 by Zinc, Age and Selenoprotein P as Composite Biomarker |
Analysis of 35 COVID-19 patients showing a significant correlation for serum zinc levels between COVID-19 patients and controls, and between COVID-19 survivors and non-survivors.
![]()
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
Late |
Vogel-González et al., medRxiv, doi:10.1101/2020.10.07.20208645 (Preprint) |
Low zinc levels at clinical admission associates with poor outcomes in COVID-19 |
| Shows a correlation between serum zinc levels and COVID-19 outcome. Almost all patients received HC Q. |
|
Positive
|
Late treatment study
|
| Vogel-González et al., medRxiv, doi:10.1101/2020.10.07.20208645 (Preprint) |
| Low zinc levels at clinical admission associates with poor outcomes in COVID-19 |
| Shows a correlation between serum zinc levels and COVID-19 outcome. Almost all patients received HC Q.
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Positive
|
Late |
Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed) |
death/hospice, ↓37.8%, p=0.002 |
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients |
| Retrospective 932 patients. Addition of Zinc to HC Q+AZ reduces mortality / transfer to hospice, ICU admission, and the need for ventilation.
Reduction in mortality or transfer to hospice adjusted odds ratio OR 0.56.. |
|
Positive
|
Late treatment study
|
| Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed) |
| Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients |
| Retrospective 932 patients. Addition of Zinc to HC Q+AZ reduces mortality / transfer to hospice, ICU admission, and the need for ventilation.Reduction in mortality or transfer to hospice adjusted odds ratio OR 0.56, p = 0.002; increase in being discharged home, adjusted OR 1.53, p = 0.008.
combined death/hospice, ↓37.8%, p=0.002
(odds ratio converted to relative risk)
|
|
Source
Study Page
Submit Corrections or Comments
|
|
In Vitro
|
In Vitro |
te Velthuis et al., PLOS Pathogens 2010, 6:11, doi:10.1371/journal.ppat.1001176 (Peer Reviewed) (In Vitro) |
Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture |
| Shows that the combination of Zn2+ and a zinc ionophore (pyrithione) at low concentrations inhibits the replication of SARS-CoV and equine arteritis virus (EAV) in cell culture. Recommends further study of the use of zinc-ionophores as an.. |
|
In Vitro
|
In Vitro
|
| te Velthuis et al., PLOS Pathogens 2010, 6:11, doi:10.1371/journal.ppat.1001176 (Peer Reviewed) (In Vitro) |
| Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture |
| Shows that the combination of Zn2+ and a zinc ionophore (pyrithione) at low concentrations inhibits the replication of SARS-CoV and equine arteritis virus (EAV) in cell culture. Recommends further study of the use of zinc-ionophores as antiviral compounds.
|
|
Source
Study Page
Submit Corrections or Comments
|
